Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Gardasil-9 for Recalcitrant Verrucae
NCT07806617Phase 2Active, not recruiting
- Sponsor
- Rush University Medical Center
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in warts, sponsored by Rush University Medical Center. Started Sep 2025; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
warts
Beyond the preview
Go deeper on NCT07806617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806617.